<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>TORNTPHARM</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">TORNTPHARM</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="torrent-pharmaceuticals-limited" class="section level1">
<h1>Torrent Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TORNTPHARM.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="analysis-of-torrent-pharmaceuticals-limited-torntpharm-as-of-november-2025" class="section level9">
<p class="heading"><strong>Analysis of Torrent Pharmaceuticals Limited (TORNTPHARM) as of November 2025</strong></p>
<p>Based on the provided documents‚Äîfinancial results, auditor reports, press releases, acquisition updates, and analyst materials‚Äîwe derive a comprehensive understanding of <strong>Torrent Pharmaceuticals Limited (TORNTPHARM)</strong> as a listed Indian pharmaceutical company. Below is a structured analysis covering its <strong>headwinds, tailwinds, growth prospects, and key risks</strong>.</p>
<hr />
</div>
<div id="overview-snapshot-q2-fy26-sept-30-2025" class="section level6">
<h6>üîç <strong>Overview Snapshot (Q2 FY26 ‚Äì Sept 30, 2025)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue (Q2)</strong></td>
<td>‚Çπ2,762 Cr (14% YoY)</td>
</tr>
<tr class="even">
<td><strong>Consolidated Revenue (Q2)</strong></td>
<td>‚Çπ3,302 Cr (14% YoY)</td>
</tr>
<tr class="odd">
<td><strong>Standalone Net Profit (Q2)</strong></td>
<td>‚Çπ597 Crores (+30% YoY)</td>
</tr>
<tr class="even">
<td><strong>Consolidated Net Profit (Q2)</strong></td>
<td>‚Çπ591 Crores (+30% YoY)</td>
</tr>
<tr class="odd">
<td><strong>Net Profit Margin</strong></td>
<td>~18% (Consolidated)</td>
</tr>
<tr class="even">
<td><strong>Operating EBITDA Margin</strong></td>
<td>32.8%</td>
</tr>
<tr class="odd">
<td><strong>R&amp;D Spend (H1)</strong></td>
<td>‚Çπ313 Crores (~5% of sales)</td>
</tr>
<tr class="even">
<td><strong>ROE (Standalone, H1)</strong></td>
<td>~27% annualized</td>
</tr>
<tr class="odd">
<td><strong>Debt-to-Equity Ratio</strong></td>
<td>0.24x (Excellent leverage position)</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="tailwinds-positive-drivers" class="section level6">
<h6>üöÄ Tailwinds (Positive Drivers)</h6>
<div id="strong-and-accelerating-revenue-growth-across-key-markets" class="section level9">
<p class="heading">1. <strong>Strong and Accelerating Revenue Growth Across Key Markets</strong></p>
<ul>
<li><strong>Overall revenue up 14% YoY (‚Çπ3,302 Cr)</strong> ‚Äî driven by strong performance in India, US, and Brazil.</li>
<li><strong>India (Domestic):</strong> Revenue at ‚Çπ1,820 Cr (+12% YoY), outperforming IPM (8%) and especially strong in <strong>chronic therapies (+13%)</strong>.</li>
<li><strong>USA:</strong> Revenue up <strong>26% YoY to ‚Çπ337 Cr</strong> ($39M at 21% constant currency), driven by successful <strong>new product launches with rapid market share capture</strong>.</li>
<li><strong>Brazil:</strong> Revenue up <strong>21% YoY (‚Çπ318 Cr)</strong>, growing <strong>15% cc vs market growth of 7%</strong>, reinforcing Torrent‚Äôs #1 position among Indian pharma players there.</li>
<li><strong>Global footprint</strong> across 50+ countries ‚Äî diversified revenue base.</li>
</ul>
<hr />
</div>
<div id="robust-profitability-with-margin-discipline" class="section level9">
<p class="heading">2. <strong>Robust Profitability with Margin Discipline</strong></p>
<ul>
<li><strong>EBITDA margin stable at 32.8%</strong>, even amid new market investments.</li>
<li><strong>Net Profit growth outpaces revenue (30% vs 14%)</strong>, indicating improved <strong>operational efficiency</strong>, favorable cost dynamics, or reduced tax burden.</li>
<li>Exceptional items (one-time acquisition costs) are transparently disclosed but did <strong>not materially impact earnings quality</strong>.</li>
</ul>
<hr />
</div>
<div id="favorable-balance-sheet-and-low-leverage" class="section level9">
<p class="heading">3. <strong>Favorable Balance Sheet and Low Leverage</strong></p>
<ul>
<li><strong>Debt-to-Equity Ratio:</strong> A strong <strong>0.24x</strong>, well below industry averages (often &gt;0.5‚Äì0.7x), giving flexibility for future M&amp;A or capex.</li>
<li><strong>Net worth:</strong> ‚Çπ8,455 Cr (up from ‚Çπ7,526 Cr YoY).</li>
<li><strong>High interest coverage ratio (22.3x)</strong> ‚Äî shows robust interest-paying capacity.</li>
<li><strong>Low financial risk</strong>, excellent liquidity with current ratio of 1.85x.</li>
</ul>
<hr />
</div>
<div id="pipeline-momentum-and-rd-strength" class="section level9">
<p class="heading">4. <strong>Pipeline Momentum and R&amp;D Strength</strong></p>
<ul>
<li><strong>76% of Indian revenues</strong> come from <strong>chronic/sub-chronic therapies</strong>, a stable and recurring-demand segment.</li>
<li>R&amp;D spend sustained at <strong>~5% of revenue (~‚Çπ156 Cr in Q2)</strong>, with <strong>750+ scientists</strong> and state-of-the-art infrastructure.</li>
<li>In <strong>Germany</strong>, despite supply issues, <strong>65 products under ANVISA review</strong> signal meaningful pipeline depth.</li>
</ul>
<hr />
</div>
<div id="strategic-acquisition-of-j.b.-chemicals-major-value-creation-opportunity" class="section level9">
<p class="heading">5. <strong>Strategic Acquisition of J.B. Chemicals ‚Äì Major Value Creation Opportunity</strong></p>
<ul>
<li>Torrent is acquiring control of <strong>J.B. Chemicals &amp; Pharma Ltd.</strong>, a high-margin specialty player.</li>
<li>Acquisition structured in <strong>two phases</strong>:
<ol style="list-style-type: decimal">
<li><strong>Purchase of 46.39% stake + potential 2.41%</strong> at ‚Çπ1,600/share (‚Çπ11,917 Cr total).</li>
<li><strong>Merger via Scheme of Arrangement</strong>: 51 shares of Torrent for every 100 shares of JB Pharma.</li>
</ol></li>
<li><strong>Acquisition approvals secured</strong> from:
<ul>
<li><strong>CCI (India)</strong> ‚Äì Oct 21, 2025<br />
</li>
<li><strong>Competition Commission South Africa</strong><br />
</li>
<li><strong>SEBI observation on Letter of Offer</strong> ‚Äì Oct 30, 2025</li>
</ul></li>
<li><strong>Starting open offer purchases (1,317 shares acquired on Dec 5, 2025)</strong> ‚Äî execution on track.</li>
</ul>
<blockquote>
<p><strong>Synergy Potential</strong>: - Complementary portfolios: JB Pharma‚Äôs strengths in <strong>dermatology, anti-infectives, and CNS</strong> align with Torrent‚Äôs focus. - Cross-selling opportunities in international markets. - Cost synergies expected post-merger.</p>
</blockquote>
<hr />
</div>
<div id="domestic-market-leadership-brand-equity" class="section level9">
<p class="heading">6. <strong>Domestic Market Leadership &amp; Brand Equity</strong></p>
<ul>
<li>Ranked <strong>7th in Indian pharma market</strong>; <strong>Top 5 in CV, GI, CNS, Dermatology</strong>.</li>
<li><strong>21 brands in AIOCD Top 500</strong>, with <strong>15 generating &gt;‚Çπ100 Cr</strong> in revenue.</li>
<li>Strong <strong>MAT (Moving Annual Total)</strong> performance indicating sustainable momentum.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6>‚ö†Ô∏è Headwinds (Challenges)</h6>
<div id="germany-operations-supply-side-disruption" class="section level9">
<p class="heading">1. <strong>Germany Operations ‚Äî Supply-Side Disruption</strong></p>
<ul>
<li><strong>Revenue declined 5% YoY in constant currency (EUR 30M ‚Üí EUR 28.5M)</strong> due to <strong>third-party manufacturing supply issues</strong>.</li>
<li>However, H1 shows +7% in INR and only -2% in constant currency ‚Äî likely <strong>temporary and resolvable</strong>.</li>
</ul>
<hr />
</div>
<div id="foreign-currency-volatility-especially-euro-real" class="section level9">
<p class="heading">2. <strong>Foreign Currency Volatility (Especially Euro &amp; Real)</strong></p>
<ul>
<li>While USD strength benefits US segment, <strong>euro weakness</strong> negatively impacts German revenue.</li>
<li>Also, <strong>BRL fluctuations</strong> could affect Brazil profitability, though cc growth is strong.</li>
</ul>
<hr />
</div>
<div id="intense-global-competition-in-generics" class="section level9">
<p class="heading">3. <strong>Intense Global Competition in Generics</strong></p>
<ul>
<li>In <strong>US</strong>, increasing competition in generic drug pricing (ANDA space) can <strong>pressure margins</strong>.</li>
<li>Success depends on <strong>speed of new launches</strong>, which Torrent is managing well ‚Äî but sustainability requires continuous innovation.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-forward-looking" class="section level6">
<h6>üîÆ Growth Prospects (Forward-Looking)</h6>
<table>
<colgroup>
<col width="30%" />
<col width="69%" />
</colgroup>
<thead>
<tr class="header">
<th>Region</th>
<th>Growth Driver</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>India</strong></td>
<td>Chronic therapy dominance, MAT outperformance, new product launches</td>
</tr>
<tr class="even">
<td><strong>USA</strong></td>
<td>Continued ANDA approvals, rapid market access, new product traction</td>
</tr>
<tr class="odd">
<td><strong>Brazil</strong></td>
<td>Market leadership, growing Rx demand, high margins</td>
</tr>
<tr class="even">
<td><strong>Germany</strong></td>
<td>Recovery from supply disruptions, potential for formulary gains</td>
</tr>
<tr class="odd">
<td><strong>J.B. Pharma Merger</strong></td>
<td><strong>Biggest growth lever</strong> ‚Äî expected to boost scale, margins, and therapeutic diversification</td>
</tr>
<tr class="even">
<td><strong>R&amp;D Pipeline</strong></td>
<td>65 products in ANVISA pipeline (Brazil) and global filings support long-term leadership</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Estimated combined revenue</strong> (Torrent + JB Pharma): ~‚Çπ18,000+ Crores ‚Äî could push Torrent into <strong>Top 3 Indian pharma players</strong> post-merger.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6>üö© Key Risks</h6>
<div id="execution-risk-in-j.b.-pharma-acquisition" class="section level9">
<p class="heading">1. <strong>Execution Risk in J.B. Pharma Acquisition</strong></p>
<ul>
<li>While regulatory approvals are secured, <strong>merger integration</strong> poses challenges:
<ul>
<li>Cultural integration</li>
<li>Operational alignment</li>
<li>Achieving <strong>expected synergies</strong></li>
</ul></li>
<li>CCI approval has <strong>voluntary modifications</strong> ‚Äî could impact deal structure or return profile.</li>
</ul>
</div>
<div id="pricing-regulatory-risks-india" class="section level9">
<p class="heading">2. <strong>Pricing &amp; Regulatory Risks (India)</strong></p>
<ul>
<li>Past <strong>NPPA litigation</strong> (2017 overcharge claim) settled ‚Äî but industry remains under pricing scrutiny.</li>
<li>Risk of future <strong>price controls</strong> or <strong>National List of Essential Medicines (NLEM)</strong> inclusion affecting margins.</li>
</ul>
</div>
<div id="dependence-on-key-therapeutic-segments" class="section level9">
<p class="heading">3. <strong>Dependence on Key Therapeutic Segments</strong></p>
<ul>
<li>High exposure to <strong>CV and GI</strong>; any regulatory, competitive, or technological shifts in these could impact results.</li>
</ul>
</div>
<div id="foreign-exchange-and-geopolitical-risk" class="section level9">
<p class="heading">4. <strong>Foreign Exchange and Geopolitical Risk</strong></p>
<ul>
<li>Earns significant revenue in USD/EUR/BRL ‚Äî <strong>FX hedging strategies</strong> will be critical.</li>
<li>Brazil and South Africa exposures carry <strong>country-specific political/economic risks</strong>.</li>
</ul>
</div>
<div id="integration-of-diverse-subsidiaries" class="section level9">
<p class="heading">5. <strong>Integration of Diverse Subsidiaries</strong></p>
<ul>
<li>18 wholly owned subsidiaries globally ‚Äî while beneficial for diversification, adds <strong>complexity to governance</strong> and <strong>control systems</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="summary-investment-outlook" class="section level6">
<h6>‚úÖ Summary &amp; Investment Outlook</h6>
<div id="verdict-strong-buy-case-with-above-industry-growth-leadership-position-and-transformative-ma-underway." class="section level9">
<p class="heading"><strong>Verdict: Strong BUY case with above-industry growth, leadership position, and transformative M&amp;A underway.</strong></p>
<table>
<thead>
<tr class="header">
<th>Factor</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue Growth</strong></td>
<td>‚úÖ‚úÖ‚úÖ‚úÖ (High and diversified)</td>
</tr>
<tr class="even">
<td><strong>Profitability</strong></td>
<td>‚úÖ‚úÖ‚úÖ‚úÖ (Improving margins)</td>
</tr>
<tr class="odd">
<td><strong>Balance Sheet</strong></td>
<td>‚úÖ‚úÖ‚úÖ‚úÖ‚úÖ (Exceptionally strong)</td>
</tr>
<tr class="even">
<td><strong>Growth Catalysts</strong></td>
<td>‚úÖ‚úÖ‚úÖ‚úÖ (J.B. Pharma + R&amp;D push)</td>
</tr>
<tr class="odd">
<td><strong>Execution Risk</strong></td>
<td>‚ö†Ô∏è‚ö†Ô∏è (Merger integration, FX)</td>
</tr>
<tr class="even">
<td><strong>Regulatory Risk</strong></td>
<td>‚ö†Ô∏è (NPPA-style scrutiny possible)</td>
</tr>
</tbody>
</table>
</div>
<div id="conclusion" class="section level9">
<p class="heading"><strong>Conclusion:</strong></p>
<p>Torrent is demonstrating <strong>best-in-class execution</strong> with: - <strong>Double-digit revenue and profit growth</strong>, - <strong>Excellent financial health</strong>, - <strong>Strategic expansion through the J.B. Pharma acquisition</strong>, which could be a <strong>step-change event</strong>.</p>
<p>Once fully integrated, the merger can position <strong>Torrent as a dominant specialty pharma player in India and globally</strong>, with <strong>enhanced chronic care, dermatology, and international scale</strong>.</p>
<p>The stock remains well-positioned for <strong>long-term value creation</strong>, though investors should monitor: - Progress on <strong>J.B. Pharma merger execution</strong>, - Recovery in <strong>Germany/EM markets</strong>, and - <strong>R&amp;D pipeline velocity</strong>.</p>
<blockquote>
<p><strong>Target Re-rating Potential</strong>: As synergy visibility improves post-merger, expect <strong>P/E re-rating</strong> from current levels (if not already priced in).</p>
</blockquote>
<hr />
<p><strong>Prepared based on publicly disclosed documents as of 13 November 2025.</strong><br />
<em>Note: All figures in Indian Rupees (crores) unless specified otherwise.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
